Navigation

Alzheimer's disease - donepezil, rivastigmine, galantamine and memantine (review)

Donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer's disease (including a review of TA19)

Status: History
Expected date of issue: November 2006
Process: MTA
Topic area:
  • Central nervous system
  • Mental health and behavioural conditions
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Meindert Boysen and Alastair Fischer
Communications manager: Sarita Tamber
Project manager: Alana Miller
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: December 2003
Information meeting with consultees: 25 March 2004
Closing date for invited submissions / evidence submission: 03 June 2004
Final scope published: January 2004
1st appraisal committee meeting: 20 October 2004
2nd appraisal committee meeting: 25 January 2005
3rd appraisal committee meeting: 01 June 2005
4th appraisal committee meeting: 20 December 2005
5th appraisal committee meeting: 27 April 2006
Top


 

Consultees and commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Eisai Ltd
  • Lundbeck
  • Novartis Pharmaceuticals Ltd
  • Shire Pharmaceuticals Ltd

Patient / Carer Groups

  • Age Concern England
  • Alzheimer's Society
  • Counsel and Care for the Elderly
  • Dementia Care Trust
  • Mental Health Foundation

Professional Groups

  • Association of British Neurologists
  • British Geriatrics Society
  • British Neuropsychiatry Association
  • For Dementia
  • Royal College of Nursing
  • RoyalCollegeof Physicians
  • RoyalCollegeof Psychiatrists
  • Royal Pharmaceutical Society

Others

  • CheshireWest PCT
  • National Collaborating Centre for Chronic Conditions
  • NHS Purchasing and Supplies Agency
  • NHS Quality Improvement Scotland

General

  • British National Formulary
  • National Collaborating Centre for Chronic Conditions
  • NHS Purchasing and supplies Agency
  • NHS Quality Improvement Scotland

Comparator Manufacturers

  • None

Assessment Team

  • None

Associated Guideline Groups

  • National Collaborating Centre for Mental Health - Guideline Development Group for Dementia

Associated Public Health Groups

  • None

Research Groups

  • Alzheimer's Research Trust
  • Demential Research Group and Department of Old Age Psychiatry, Institute of Psychiatry
  • Institute for Aging and Health
  • Research Institute for the Care of the Elderly

Top


 

Project history

Date Update
6 February 2004 Please note that the Institute held a consultation exercise in December 2003 & January 2004 on two draft scopes relating to the treatment of Alzheimer's disease and, in response to responses to the consultation, has decided to combine these appraisals. This change does not alter the scheduled timelines.
12 March 2004 Information meeting for consultees to take place on 25 March 2004.
27 August 2004 Technical leads updated.
16 November 2004 Following the Appraisal Committee meeting held on the 20 October 2004 the committee has agreed that further analysis of the cost effectiveness of the technology will be undertaken on behalf of the Institute for consideration by the Appraisal Committee at a future meeting (date to be confirmed). Further details will be sent to consultees and commentators and published on the NICE website as soon as they are available.
29 December 2004 Specification for extra work on cost effectiveness added.
25 January 2005 Project manager updated.
7 March 2005 Final matrix amended, summary updated.
19 July 2005 The Appraisal Committee met on 1 April to discuss comments received on the Appraisal Consultation Document, and to prepare a Final Appraisal Determination (FAD). The Institute has not issued the FAD to allow more time for further data collection. The Institute will be making a specific request to the pharmaceutical companies involved in the appraisal for further individual subject level analysis from their pivotal clinical trials. Details of this request can be found below. Responses to our request for further information will be considered by the Appraisal Committee in October 2005. The timelines will be reviewed following this date in light of the decisions made by the Appraisal Committee. The Institute is not asking for any other comments or evidence to be forwarded at this time.
8 August 2005 Letter to manufacturers and Project specification form added.
12 August 2005 The Institute released sections of the unpublished FAD which refer specifically to the Appraisal Committee?s consideration of the sub-group issue to ensure that consultees have a good understanding of why we have made a request for further information.
7 December 2005 4th Appraisal committee meeting date corrected to 20 December 2005
26 May 2006 Final matrix amended, summary updated.
13 July 2006 The Institute received five appeals from Alzheimer's Society, Age Concern, Counsel and Care, Dementia Care Trust and Royal College of Nursing (joint appeal), Eisai Ltd, Lundbeck Ltd, Royal College of Psychiatrists & British Geriatrics Society (joint appeal) and Shire Pharmaceuticals Ltd against the Final Appraisal Determination and Guidance on this technology. An appeal hearing was held on 13 & 14 July.
Top


 

Key documents

This page was last updated: 15 February 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.